Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 5, 2008
Guest: Dan Vogl, M.D.
Date: Monday, December 8, 2008
Time: 10:00 – 10:30 am Pacific
Where to Listen: www.patientpower.info
Email questions in advance or during the live show to: Questions@patientpower.info
Oct 23, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.
Oct 23, 2014
Dec 13, 2010
May 3, 2012